TFAM and Mitochondrial Protection in Diabetic Kidney Disease
Siming Yu,Xinxin Lu,Chunsheng Li,Zehui Han,Yue Li,Xianlong Zhang,Dandan Guo
DOI: https://doi.org/10.2147/dmso.s487815
2024-11-27
Diabetes Metabolic Syndrome and Obesity Targets and Therapy
Abstract:Siming Yu, 1, 2 Xinxin Lu, 2 Chunsheng Li, 2 Zehui Han, 2 Yue Li, 2 Xianlong Zhang, 3 Dandan Guo 2, 4 1 The First Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, Harbin, People's Republic of China; 2 Heilongjiang University of Traditional Chinese Medicine, Harbin, China; 3 The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China; 4 The Second Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, Harbin, People's Republic of China Correspondence: Dandan Guo, The Second Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, Harbin, People's Republic of China, Email Xianlong Zhang The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China, Email Diabetic kidney disease (DKD) is a significant complication of diabetes and a major cause of end-stage renal disease. Affecting around 40% of diabetic patients, DKD poses substantial economic burdens due to its prevalence worldwide. The primary clinical features of DKD include the leakage of proteins into the urine, altered glomerular filtration, and an increased risk of cardiovascular diseases. Current treatments focus on managing hypertension and hyperglycemia to slow the progression of DKD. These include the use of SGLT2 inhibitors to control blood sugar and ACE inhibitors to reduce blood pressure. Despite these measures, current treatments do not cure DKD and fail to address its underlying causes. Emerging research highlights mitochondrial dysfunction as a pivotal factor in DKD progression. The kidneys' high energy requirements make them particularly susceptible to disturbances in mitochondrial function. In DKD, mitochondrial damage leads to reduced energy production and increased oxidative stress, exacerbating tissue damage. Mitochondrial DNA (mtDNA) damage is a key aspect of this dysfunction, with studies suggesting that changes in mtDNA copy number can serve as biomarkers for the progression of the disease. Efforts to target mitochondrial dysfunction are gaining traction as a potential therapeutic strategy. This includes promoting mitochondrial health through pharmacological and lifestyle interventions aimed at enhancing mitochondrial function and reducing oxidative stress. Such approaches could lead to more effective treatments that directly address the DKD. Keywords: diabetic kidney disease, TFAM, mitochondrial dysfunction, mitochondrial DNA, oxidative stress Diabetic kidney disease (DKD) is a prevalent microvascular complication among diabetes patients and a primary cause of end-stage renal disease. 1 Epidemiological studies indicate that nearly 40% of individuals with diabetes are affected by DKD, with its prevalence remaining relatively stable. 2 However, due to the vast number of people with diabetic nephropathy worldwide, DKD has escalated into a significant public health issue, imposing substantial economic burdens on both society and healthcare systems. Clinical manifestations of DKD include the leakage of albumin, metabolites, and ions into the urine, alterations in glomerular filtration rate, and an increased risk of cardiovascular disease and stroke. 3 Current pharmacological strategies for managing DKD primarily target hypertension and hyperglycemia, aiming to slow disease progression. 4 Medications such as SGLT2 inhibitors are used to control blood glucose levels, while ACE inhibitors and angiotensin receptor blockers target the renin-angiotensin system. These medications lower glomerular pressure, dilate small renal efferent arterioles, and reduce albumin excretion, with the goal of slowing the progression of DKD and preventing cardiovascular complications. However, these treatments do not address the underlying causes of DKD. Lifestyle modifications, including weight management, reducing salt intake, regular exercise, and dietary changes, have also proven beneficial in managing DKD by lowering blood pressure and reducing proteinuria. Despite the comprehensive application of these interventions, current treatment approaches cannot completely halt or reverse the progression of DKD. Thus, there is a critical need for the development of more effective and targeted therapies to overcome the clinical limitations of existing DKD treatments. 4 To address the challenge posed by DKD, targeting mitochondrial dysfunction has recently emerged as a promising strategy to halt disease progression. Mitochondria are the primary organelles responsible for energy production in the kidneys, whether in a healthy state or during DKD. The substantial energy and oxygen requirements of the kidn -Abstract Truncated-
endocrinology & metabolism